Semax is a synthetic heptapeptide built from the ACTH(4–10) fragment and a stabilizing Pro-Gly-Pro tail. This article reviews how the research literature characterizes its interaction with ACTH-derived and melanocortin-linked signaling, and what rodent and in-vitro models actually show about neurotrophin, neurotransmission, and inflammatory gene regulation.

What Semax is and how its ACTH(4–10) origin shapes activity

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its first four residues correspond to the 4–7 region of adrenocorticotropic hormone (ACTH), extended by the C-terminal tripeptide Pro-Gly-Pro (PGP). This design was intended to retain the neuroactive character associated with the ACTH(4–10) region while removing the peptide's classical steroidogenic endocrine role.³ In the literature the molecule is frequently described as a melanocortin derivative, reflecting the melanocortin lineage of ACTH.⁶

The Pro-Gly-Pro extension is more than a spacer. Investigators report that the PGP tail is associated with slower enzymatic degradation of the peptide in biological preparations, and studies that compare Semax against PGP alone have found that the two fragments produce overlapping but distinguishable transcriptional profiles in the ischemic rodent cortex.¹ That comparison is analytically useful: it lets researchers separate effects attributable to the ACTH-derived core from those attributable to the terminal tripeptide.

Because the fragment omits the residues required for the full hormone's endocrine cascade, Semax is studied primarily as a modulator of central signaling rather than as a hypothalamic-pituitary-adrenal agonist. This framing recurs across the mechanistic papers and is the reason the compound is examined in cognition, ischemia, and neurodevelopmental models rather than in endocrine assays.⁵ Researchers comparing structurally related peptides such as Selank often place Semax within the same family of short regulatory peptides derived from endogenous sequences.

How Semax engages ACTH-derived and melanocortin signaling

The core mechanistic question is how a short ACTH fragment reaches intracellular transcriptional machinery. Binding studies in rat basal forebrain membranes report specific, reversible, calcium-dependent binding sites for tritium-labelled Semax, with a dissociation constant in the low-nanomolar range.³ That finding is significant because it suggests the peptide engages defined membrane targets rather than acting only through non-specific uptake, and because the calcium dependence links its binding to calcium- and cAMP-associated signaling cascades that are repeatedly flagged in downstream transcriptomic analyses.⁴

Pathway-enrichment analyses of Semax-responsive genes recurrently identify "neuroactive ligand–receptor interaction" and calcium/cAMP-linked signaling among the most affected categories.⁸ In the most recent regional study, genes overlapping between Semax and a related ACTH(6–9)PGP peptide, across two brain regions, were associated predominantly with neuroactive ligand–receptor interaction — consistent with the idea that the shared ACTH-derived scaffold channels activity toward these networks.² The melanocortin heritage of the sequence is often cited as the structural basis for this selectivity, although direct high-affinity agonism at classical melanocortin receptors is not the mechanism these transcriptomic datasets describe.

Taken together, the reported picture is one of indirect transcriptional modulation: a protease-resistant ACTH-derived fragment binds defined central sites, couples to calcium- and cAMP-associated signaling, and shifts the expression of gene programs governing neurotransmission, trophic support, and immune tone. Each of those downstream arms is examined in more detail below.

Molecular links between Semax and neurotrophic factor regulation

One of the most consistently reported observations is that Semax exposure is associated with increased brain-derived neurotrophic factor (BDNF) signaling in rodent tissue. In rat basal forebrain, intranasal Semax was followed by a rapid rise in BDNF protein at three hours in that region but not in the cerebellum, indicating regional specificity of the response.³ In the hippocampus, a single application was reported to raise BDNF protein and exon-III BDNF mRNA together with increased TrkB receptor phosphorylation and mRNA, alongside changes in a conditioned avoidance task.⁵

At the transcriptional level, cerebral-ischemia experiments describe induction of neurotrophins and their receptor genes. Following permanent middle cerebral artery occlusion, both Semax and PGP were reported to activate transcription of Bdnf, Ngf, Nt-3 and the Trk receptors in the cortex, with Semax selectively affecting these transcripts in ischemic tissue while PGP's influence was described as largely non-specific.¹ A separate study of incomplete global ischemia reported that the decrease in neurotrophin and receptor mRNA caused by occlusion was counteracted by Semax and PGP, most notably in the hippocampus.¹²

These results are frequently interpreted as evidence that the cognitive and neuroprotective effects reported for Semax in rodents may be partly downstream of BDNF/TrkB regulation.⁵ That interpretation remains a mechanistic hypothesis grounded in rodent and cell-culture data rather than a validated human pathway.

Experimental models: transcriptomic and synaptic readouts

The bulk of the mechanistic literature uses rodent focal-ischemia paradigms — permanent (pMCAO) or transient (tMCAO) middle cerebral artery occlusion — combined with microarray or RNA-Seq profiling. In these models Semax is characterized less by a single behavioural endpoint than by broad transcriptional reprogramming. A genome-wide RNA-Seq analysis in the tMCAO model identified 394 differentially expressed genes in Semax-treated versus saline-treated rat brain at 24 hours, and summarized the pattern as suppression of inflammation-related genes with activation of neurotransmission-related genes — the mirror image of the ischemia-only profile.⁴

Protein-level work supports the transcriptomic reading. In a tMCAO study, active CREB was reported to be upregulated in subcortical structures while MMP-9, c-Fos and active JNK were downregulated in adjacent cortex under Semax, linking the gene-expression signature to proteins involved in cell death, inflammation, and recovery signaling.⁶ The table below summarizes representative primary studies and their reported readouts.

An important caveat runs through this body of work: most endpoints are gene-network or protein-expression measures rather than electrophysiological or detailed cognitive assessments. The transcriptomic signatures align with earlier behavioural reports on ACTH-derived peptides and learning, but the datasets themselves largely describe molecular reprogramming, not validated functional outcomes.⁴

Inflammatory and immune gene networks

Across independent genome-wide studies, the immune response emerges as the process most markedly affected by Semax after ischemia. An early microarray study reported that immune-related genes represented more than half of the transcripts whose expression Semax altered, with chemokine- and immunoglobulin-encoding genes forming prominent clusters, and additional effects on vascular-system genes involved in endothelial development and vasculogenesis.⁸ A later analysis framed the peptide's action as neuroimmune crosstalk, describing modulation of antigen-presentation and interferon-signaling pathways.⁷

Because some key pro-inflammatory transcripts sit at expression levels too low for reliable RNA-Seq quantification, a targeted qRT-PCR study examined them directly and reported that Semax was associated with statistically significant decreases in Il1a, Il1b, Il6, Ccl3 and Cxcl2 mRNA, compensating for the ischemia-reperfusion-induced rise in these transcripts.¹⁰ A parallel comparison of Semax with the ACTH(6–9)PGP peptide in the early post-stroke window (4.5 hours) found that both partially counteracted ischemia-driven changes in immune- and neurosignaling genes, while differing in which immune transcripts each peptide affected most.⁹

In mechanistic terms, dampening of chemokine and innate-immune transcription is described as lowering the transcriptional "noise" of stress-induced neuroimmune activation, which the authors relate to the clearer neurotrophic and neurotransmission signatures observed in the same tissue.⁷ This remains an association drawn from rodent transcriptomics rather than a demonstrated causal chain.

Region-specific modulation: cortex versus striatum

The most recent regional study is instructive about the limits of the peptide's reach. Using the same animals from which frontal-cortex tissue had previously been profiled, investigators analyzed the striatum — the region containing the primary ischemic focus — and reported that the peptides generated far fewer differentially expressed genes there than in the cortex.² In the penumbra-associated frontal cortex, the peptides reduced ischemia-induced disturbance for close to two thousand genes; in the striatum the responsive set was measured in the hundreds, and for the related ACTH(6–9)PGP peptide 152 genes showed an even more disturbed profile.²

This gradient is usually interpreted as reflecting tissue viability: the penumbral cortex retains more salvageable cellular machinery capable of a compensatory transcriptional response, whereas the severely injured striatal core has constrained capacity to respond. The observation matters for experimental design, because it implies that where a sample is taken can determine whether a Semax-associated signature is detected at all.²

Evidence level and regulatory status

The mechanistic case for Semax rests on a coherent but narrow evidence base. The binding data are from rodent membrane preparations;³ the neurotrophin, neurotransmission, and immune signatures are from rat ischemia models profiled by microarray, RNA-Seq, and qRT-PCR;¹⁴¹⁰ and behavioural readouts, where present, are rodent tasks.¹¹ Independent large-scale human randomized controlled trials meeting international standards are not the basis of this literature. Claims about human outcomes should therefore be treated as unestablished.

Regulatory status reinforces that caution. Semax is registered and used as a pharmaceutical within the Russian Federation, where much of the primary research originates. It is not approved by the U.S. Food and Drug Administration or the European Medicines Agency, and it is not an established therapeutic outside that jurisdiction. Qovigen supplies Semax strictly as a research chemical for in-vitro and preclinical laboratory use.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.